Effect of intravenous iron therapy on exercise performance, fatigue scores and mood states in iron-deficient recreationally active females of reproductive age: a double-blind, randomised control trial (IRONWOMAN Trial)
{"title":"Effect of intravenous iron therapy on exercise performance, fatigue scores and mood states in iron-deficient recreationally active females of reproductive age: a double-blind, randomised control trial (IRONWOMAN Trial)","authors":"Cory Dugan, Peter Peeling, Paige Buissink, Beth MacLean, Jayne Lim, Pradeep Jayasuriya, Toby Richards","doi":"10.1136/bjsports-2024-108240","DOIUrl":null,"url":null,"abstract":"Objectives Non-anaemic iron deficiency (IDNA) is highly prevalent in exercising females. Although iron therapy can be used to correct this issue, its impact on exercise performance is equivocal. Our aim was to assess the efficacy of intravenous iron therapy on exercise performance, fatigue, mood states, and quality of life in recreationally active IDNA females of reproductive age. Methods Twenty-six recreationally active IDNA females were randomised to either an intravenous iron treatment (IRON) group or placebo (PLA). Prior to, 4 days and 4 weeks following intervention, participants completed a variety of assessments to determine changes in exercise performance, haemoglobin mass, blood iron status and haematology, fatigue levels, mood states and quality of life. Results Intravenous iron therapy significantly improved serum ferritin, serum iron and transferrin saturation (p<0.05), with a highly variable individual response. No differences were observed between groups’ peak oxygen consumption (V̇O2Peak), lactate threshold or haemoglobin mass. Running economy improved in IRON from baseline to 4 weeks (p<0.05), which was also different to PLA at 4 weeks (p<0.05). Fatigue scores improved in IRON but not PLA after 4 weeks (p<0.05). Mood states and quality of life remained unchanged in both groups over the trial. Conclusion In recreationally active IDNA females, intravenous iron therapy corrects iron status and improves both exercise economy and fatigue scores after 4 weeks. Trial registration number ACTRN12620001357943. Data are available upon reasonable request. To adhere to ICMJE guidelines, a data sharing plan is included with trial registration (ACTRN12620001357943). Data will be made available following the published date for the purposes of generating empirical knowledge through research collaboration, for example, systematic reviews and meta-analyses (inclusive of individual patient data meta-analyses). Requests to obtain data can be made by emailing the principal investigator (cory.dugan@research.uwa.edu.au).","PeriodicalId":9276,"journal":{"name":"British Journal of Sports Medicine","volume":"35 1","pages":""},"PeriodicalIF":11.6000,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"British Journal of Sports Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1136/bjsports-2024-108240","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"SPORT SCIENCES","Score":null,"Total":0}
引用次数: 0
Abstract
Objectives Non-anaemic iron deficiency (IDNA) is highly prevalent in exercising females. Although iron therapy can be used to correct this issue, its impact on exercise performance is equivocal. Our aim was to assess the efficacy of intravenous iron therapy on exercise performance, fatigue, mood states, and quality of life in recreationally active IDNA females of reproductive age. Methods Twenty-six recreationally active IDNA females were randomised to either an intravenous iron treatment (IRON) group or placebo (PLA). Prior to, 4 days and 4 weeks following intervention, participants completed a variety of assessments to determine changes in exercise performance, haemoglobin mass, blood iron status and haematology, fatigue levels, mood states and quality of life. Results Intravenous iron therapy significantly improved serum ferritin, serum iron and transferrin saturation (p<0.05), with a highly variable individual response. No differences were observed between groups’ peak oxygen consumption (V̇O2Peak), lactate threshold or haemoglobin mass. Running economy improved in IRON from baseline to 4 weeks (p<0.05), which was also different to PLA at 4 weeks (p<0.05). Fatigue scores improved in IRON but not PLA after 4 weeks (p<0.05). Mood states and quality of life remained unchanged in both groups over the trial. Conclusion In recreationally active IDNA females, intravenous iron therapy corrects iron status and improves both exercise economy and fatigue scores after 4 weeks. Trial registration number ACTRN12620001357943. Data are available upon reasonable request. To adhere to ICMJE guidelines, a data sharing plan is included with trial registration (ACTRN12620001357943). Data will be made available following the published date for the purposes of generating empirical knowledge through research collaboration, for example, systematic reviews and meta-analyses (inclusive of individual patient data meta-analyses). Requests to obtain data can be made by emailing the principal investigator (cory.dugan@research.uwa.edu.au).
期刊介绍:
The British Journal of Sports Medicine (BJSM) is a dynamic platform that presents groundbreaking research, thought-provoking reviews, and meaningful discussions on sport and exercise medicine. Our focus encompasses various clinically-relevant aspects such as physiotherapy, physical therapy, and rehabilitation. With an aim to foster innovation, education, and knowledge translation, we strive to bridge the gap between research and practical implementation in the field. Our multi-media approach, including web, print, video, and audio resources, along with our active presence on social media, connects a global community of healthcare professionals dedicated to treating active individuals.